Wave Life Sciences Ltd. (WVE) Stock Forecast
WVE analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.70 / 5 from 20 analysts
- Price target
- $17.22 average of analyst targets
- Upside to target
- +450.1% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.33
- 52-week range
- $3.09 – $21.31
WVE analyst ratings
20 analystsNumber of analysts at each rating.
WVE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
WVE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.32 | −$0.37 | −$0.25 | −$0.32 | −1.1% | 17 |
| Current fiscal year (2026) | −$1.10 | −$1.22 | −$0.87 | −$1.21 | +8.7% | 17 |
| Next fiscal year (2027) | −$1.17 | −$1.68 | −$0.07 | −$1.10 | −5.6% | 18 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
WVE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $4.4M | $0 | $20.0M | −42.3% | 19 |
| Current fiscal year (2026) | $50.6M | $38.2M | $83.0M | +18.4% | 19 |
| Next fiscal year (2027) | $35.2M | $0 | $134.0M | −30.4% | 19 |
WVE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
WVE revenue: reported and forecast
WVE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.31 | −$0.32 | −$0.32 | −$0.32 | −$0.32 | +5.5% | 0 up · 0 down |
| Current fiscal year (2026) | −$0.84 | −$1.11 | −$1.10 | −$1.10 | −$1.10 | +31.9% | 0 up · 0 down |
| Next fiscal year (2027) | −$1.08 | −$1.19 | −$1.14 | −$1.16 | −$1.17 | +7.6% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
WVE earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; WVE beat in 4 of 12.
What analysts expect from WVE
20 analysts cover Wave Life Sciences; their consensus rating is strong buy (4.70 on a 1–5 scale, where 5 is a strong buy). The average price target is $17.22, 450.1% above the latest close of $3.13. Analysts expect earnings of −$1.10 per share for 2026, +8.7% from a year earlier. For 2027 the average estimate is −$1.17 per share on revenue of $35.2 million. Wave Life Sciences beat the EPS estimate in 4 of the last 12 quarters.
Related: WVE income statement, WVE key metrics, WVE chart. See the WVE stock overview for the latest quote and news.
WVE forecast FAQ
What is Wave Life Sciences's price target?
The average analyst price target for Wave Life Sciences is $17.22, 450.1% above the latest close of $3.13.
Is Wave Life Sciences a buy, hold or sell?
Of 20 analysts covering Wave Life Sciences, 16 rate it a strong buy, 2 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Wave Life Sciences's EPS forecast?
Analysts forecast −$1.10 per share for 2026 (range −$1.22 to −$0.87); for 2027 the estimate is −$1.17.
What is Wave Life Sciences's revenue forecast?
The average revenue estimate for 2026 is $50.6 million, growth of 18.4%; for 2027 it is $35.2 million.
When does Wave Life Sciences report earnings?
Wave Life Sciences is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 before the market opens; the EPS estimate is $-0.33.
Does Wave Life Sciences usually beat earnings estimates?
Wave Life Sciences reported EPS at or above the analyst estimate in 4 of the last 12 quarters.